Clinical trial
Evaluation of Fulvic Acid Supplementation for the Attenuation of Symptoms Associated With Metabolic Syndrome
NCT07927283 is registered in ClinicalTrials.gov with Arizona State University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of Fulvic Acid Supplementation for the Attenuation of Symptoms Associated With Metabolic Syndrome
- Lead sponsor
- Arizona State University
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- November 6, 2026
- Completion date
- November 15, 2027
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 3 arms.
-
Fulvic acid 50
50 mg
-
Fulvic acid 100
100 mg
-
Placebo
cornstarch
Primary endpoints
Registered primary outcome measures; 5 primary.
-
girth
waist circumference in cm
-
hypertension
diastolic and systolic blood pressure
-
hyperglycemia
fasting blood glucose
-
hypertriglyceridemia
fasting blood triglycerides
-
cholesterol
fasting blood HDL cholesterol
Lead sponsor's other trials
Arizona State University, most recent start first.
+232 more trials See the organization page
Similar trials
Same condition (Glucose Intolerance) and phase, most recent start first.
+480 more trials See the condition page